Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Interferon beta-1b
Drug ID BADD_D01170
Description Human interferon beta (165 residues), cysteine 17 is substituted with serine. Produced in E. coli, no carbohydrates, MW=18.5kD
Indications and Usage Interferon beta-1b is a drug used for the treatment of relapsing/remitting multiple sclerosis. It has been shown to slow the advance of the disease as well as to decrease the frequency of attacks.
Marketing Status approved
ATC Code L03AB08
DrugBank ID DB00068
KEGG ID D00746
MeSH ID D000068576
PubChem ID Not Available
TTD Drug ID D0CQ2O
NDC Product Code 0078-0569; 50419-524
UNII TTD90R31WZ
Synonyms Interferon beta-1b | Beta-IFN-1b | Ser(17) IFN-beta | Interferon Beta, Serine(17) | Serine(17) Interferon Beta | Interferon beta 1b | IFN-Beta Ser | Interferon Beta, Ser(17) | Betaseron | Beta-Seron | Beta Seron | Extavia | Betaferon
Chemical Information
Molecular Formula Not Available
CAS Registry Number 145155-23-3
SMILES Not Available
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hyperuricaemia14.09.01.003--
Hypocalcaemia14.04.01.004--
Hypothyroidism14.11.01.012; 05.02.03.001--
Influenza like illness08.01.03.010--
Injection site hypersensitivity12.07.03.006; 10.01.03.017; 08.02.03.006--Not Available
Injection site inflammation12.07.03.009; 08.02.03.008--Not Available
Injection site mass08.02.03.009; 12.07.03.010--Not Available
Injection site necrosis12.07.03.020; 08.02.03.020--Not Available
Injection site oedema12.07.03.024; 08.02.03.024--Not Available
Injection site pain12.07.03.011; 08.02.03.010--Not Available
Injection site reaction08.02.03.014; 12.07.03.015--
Insomnia19.02.01.002; 17.15.03.002--
Leukopenia01.02.02.001--Not Available
Lymphadenopathy01.09.01.002--Not Available
Lymphocyte count decreased13.01.06.006--
Lymphopenia01.02.02.002--Not Available
Malaise08.01.01.003--
Menstruation irregular21.01.01.005; 05.05.01.008--
Micturition urgency20.02.02.006--
Muscular weakness17.05.03.005; 15.05.06.001--
Myalgia15.05.02.001--
Nausea07.01.07.001--
Neutrophil count decreased13.01.06.010--
Oedema peripheral08.01.07.007; 14.05.06.011; 02.05.04.007--
Pain08.01.08.004--
Palpitations02.11.04.012--
Pancreatitis07.18.01.001--
Paraesthesia23.03.03.094; 17.02.06.005--
Pneumonia22.07.01.003; 11.01.09.003--Not Available
Pruritus23.03.12.001--
The 2th Page    First    Pre   2 3    Next   Last    Total 3 Pages